Preventive strategies in familial and hereditary colorectal cancer

Morgan, 2023, Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN, Gut, 72, 338, 10.1136/gutjnl-2022-327736 Murphy, 2019, Lifestyle and dietary environmental factors in colorectal cancer susceptibility, Mol Aspect Med, 69, 2, 10.1016/j.mam.2019.06.005 Carr, 2018, Healthy lifestyle factors associated with lower risk of colorectal cancer irrespective of genetic risk, Gastroenterology, 155, 10.1053/j.gastro.2018.08.044 Katona, 2020, Chemoprevention of colorectal cancer, Gastroenterology, 158, 368, 10.1053/j.gastro.2019.06.047 Silva, 2021, Effect of metabolic syndrome and individual components on colon cancer characteristics and prognosis, Front Oncol, 11, 10.3389/fonc.2021.631257 Zaytseva, 2021, Lipid metabolism as a targetable metabolic vulnerability in colorectal cancer, Cancers, 13, 10.3390/cancers13020301 Komninou, 2003, Insulin resistance and its contribution to colon carcinogenesis, Exp Biol Med (Maywood), 228, 396, 10.1177/153537020322800410 Siegel, 2020, Colorectal cancer statistics, 2020, Ca - Cancer J Clin, 70, 145, 10.3322/caac.21601 Stoffel, 2020, Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults, Gastroenterology, 158, 341, 10.1053/j.gastro.2019.07.055 Barrus, 2022, Somatic tumor testing implications for Lynch syndrome germline genetic testing, Cancer Genet, 264-265, 16, 10.1016/j.cancergen.2022.02.010 National Comprehensive Cancer Network, 2022 Hampel, 2016, Genetic counseling and cascade genetic testing in Lynch syndrome, Fam Cancer, 15, 423, 10.1007/s10689-016-9893-5 Frankel, 2019 Win, 2017, Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American association for cancer research, Am Soc Prev Oncol, 26, 404 Lynch, 1971, Cancer family “G” revisited: 1895‐1970, Cancer, 27, 1505, 10.1002/1097-0142(197106)27:6<1505::AID-CNCR2820270635>3.0.CO;2-L Boland, 2005, Evolution of the nomenclature for the hereditary colorectal cancer syndromes, Fam Cancer, 4, 211, 10.1007/s10689-004-4489-x Hampel, 2018, Population screening for hereditary colorectal cancer, Surg Oncol Clin N Am, 27, 319, 10.1016/j.soc.2017.11.006 Cerretelli, 2020, Molecular pathology of Lynch syndrome, J Pathol, 250, 518, 10.1002/path.5422 Ahadova, 2021, The "unnatural" history of colorectal cancer in Lynch syndrome: lessons from colonoscopy surveillance, Int J Cancer, 148, 800, 10.1002/ijc.33224 Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I Jass, 1992, Evolution of hereditary non-polyposis colorectal cancer, Gut, 33, 783, 10.1136/gut.33.6.783 Bonadona, 2011, Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome, JAMA, 305, 2304, 10.1001/jama.2011.743 Dowty, 2013, Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat, 34, 490, 10.1002/humu.22262 Dominguez-Valentin, 2020, Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database, Genet Med, 22, 15, 10.1038/s41436-019-0596-9 Moller, 2017, Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database, Gut, 66, 1657, 10.1136/gutjnl-2016-311403 Jarvinen, 2000, Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer, Gastroenterology, 118, 829, 10.1016/S0016-5085(00)70168-5 Seppala, 2021, Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD), Fam Cancer, 20, 35, 10.1007/s10689-020-00193-2 Malik, 2018, Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis, Fam Cancer, 17, 557, 10.1007/s10689-017-0062-2 Duclos, 2014, Immediate outcome, long-term function and quality of life after extended colectomy with ileorectal or ileosigmoid anastomosis, Colorectal Dis, 16, O288, 10.1111/codi.12558 Monahan, 2020, Guidelines for the management of hereditary colorectal cancer from the British society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom cancer genetics group (UKCGG), Gut, 69, 411, 10.1136/gutjnl-2019-319915 Seppala, 2021, European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender, Br J Surg, 108, 484, 10.1002/bjs.11902 Herzig, 2017, The American society of colon and rectal surgeons clinical practice guidelines for the management of inherited polyposis syndromes, Dis Colon Rectum, 60, 881, 10.1097/DCR.0000000000000912 Cercek, 2022, PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer, N Engl J Med, 386, 2363, 10.1056/NEJMoa2201445 Doerner, 2022, 3, 185 Baucom, 2012, Endoscopic and surgical management of hereditary nonpolyposis colorectal cancer, Clin Colon Rectal Surg, 25, 90, 10.1055/s-0032-1313779 McNamara, 2016, Is there a role for prophylactic colectomy in Lynch syndrome patients with inflammatory bowel disease?, Int J Colorectal Dis, 31, 9, 10.1007/s00384-015-2398-0 International Mismatch Repair, 2021, Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study, Lancet Oncol, 22, 1014, 10.1016/S1470-2045(21)00189-3 Burn, 2011, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial, Lancet, 378, 2081, 10.1016/S0140-6736(11)61049-0 Algra, 2012, Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol, 13, 518, 10.1016/S1470-2045(12)70112-2 Mathers, 2022 Macaron, 2022, Chemoprevention considerations in patients with hereditary colorectal cancer syndromes, Gastrointest Endosc Clin N Am, 32, 131, 10.1016/j.giec.2021.08.005 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Jeter, 2019 Aronson, 2022, Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group, J Med Genet, 59, 318, 10.1136/jmedgenet-2020-107627 Tabori, 2017, Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood, Clin Cancer Res, 23, e32, 10.1158/1078-0432.CCR-17-0574 Picó, 2020, Clinical and pathological characterization of lynch-like syndrome, Clin Gastroenterol Hepatol, 18, 10.1016/j.cgh.2019.06.012 Nugroho, 2023, Risk of cancer in individuals with Lynch-like syndrome and their families: a systematic review, J Cancer Res Clin Oncol, 149, 25, 10.1007/s00432-022-04397-0 Rodriguez-Soler, 2013, Risk of cancer in cases of suspected lynch syndrome without germline mutation, Gastroenterology, 144, 926, 10.1053/j.gastro.2013.01.044 Adar, 2017, A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome, Mod Pathol, 30, 440, 10.1038/modpathol.2016.211 Gylling, 2009, Large genomic rearrangements and germline epimutations in Lynch syndrome, Int J Cancer, 124, 2333, 10.1002/ijc.24230 Leclerc, 2018, Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation, Genet Med, 20, 1589, 10.1038/gim.2018.47 Bisgaard, 1994, Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate, Hum Mutat, 3, 121, 10.1002/humu.1380030206 Feldman, 2010, 1 van Leerdam, 2019, Endoscopic management of polyposis syndromes: European society of gastrointestinal endoscopy (ESGE) guideline, Endoscopy, 51, 877, 10.1055/a-0965-0605 Vasen, 2008, Guidelines for the clinical management of familial adenomatous polyposis (FAP), Gut, 57, 704, 10.1136/gut.2007.136127 Matsumoto, 2002, Genetic predisposition to clinical manifestations in familial adenomatous polyposis with special reference to duodenal lesions, Am J Gastroenterol, 97, 180, 10.1111/j.1572-0241.2002.05434.x Bulow, 2004, Duodenal adenomatosis in familial adenomatous polyposis, Gut, 53, 381, 10.1136/gut.2003.027771 Burke, 2020, Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis, N Engl J Med, 383, 1028, 10.1056/NEJMoa1916063 Balaguer, 2022, Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: post hoc analysis of a randomized clinical trial, Dis Colon Rectum, 65, 536, 10.1097/DCR.0000000000002095 Samadder, 2018, Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial, JAMA Oncol, 4, 671, 10.1001/jamaoncol.2017.5431 Samadder, 2023, Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis, Gut, 72, 256, 10.1136/gutjnl-2021-326532 Kemp Bohan, 2021, Chemoprevention in familial adenomatous polyposis: past, present and future, Fam Cancer, 20, 23, 10.1007/s10689-020-00189-y Breen, 2022, An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes, Genet Med, 24, 2587, 10.1016/j.gim.2022.08.027 Katona, 2018, A counseling framework for moderate-penetrance colorectal cancer susceptibility genes, Genet Med, 20, 1324, 10.1038/gim.2018.12 Lammi, 2004, Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer, Am J Hum Genet, 74, 1043, 10.1086/386293 Marvin, 2011, AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome, Am J Med Genet A, 155A, 898, 10.1002/ajmg.a.33927 Rivera, 2014, A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia, Eur J Hum Genet, 22, 423, 10.1038/ejhg.2013.146 Jelsig, 2021, Novel genetic causes of gastrointestinal polyposis syndromes, Appl Clin Genet, 14, 455, 10.2147/TACG.S295157 Valle, 2019, Update on genetic predisposition to colorectal cancer and polyposis, Mol Aspect Med, 69, 10, 10.1016/j.mam.2019.03.001 Palles, 2013, Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas, Nat Genet, 45, 136, 10.1038/ng.2503 He, 2021, Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor, Ann Transl Med, 9, 129, 10.21037/atm-20-7553 Weren, 2018, NTHL1 and MUTYH polyposis syndromes: two sides of the same coin?, J Pathol, 244, 135, 10.1002/path.5002 Stjepanovic, 2019, Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 1558, 10.1093/annonc/mdz233 Stanich, 2019, Prevalence of germline mutations in polyposis and colorectal cancer-associated genes in patients with multiple colorectal polyps, Clin Gastroenterol Hepatol, 17, 2008, 10.1016/j.cgh.2018.12.008 Grover, 2012, Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas, JAMA, 308, 485, 10.1001/jama.2012.8780 Dettwyler, 2022, Outcomes of retesting in patients with previously uninformative cancer genetics evaluations, Fam Cancer, 21, 375, 10.1007/s10689-021-00276-8 Ciavarella, 2018, Somatic APC mosaicism and oligogenic inheritance in genetically unsolved colorectal adenomatous polyposis patients, Eur J Hum Genet, 26, 387, 10.1038/s41431-017-0086-y Yurgelun, 2014, Therapy-associated polyposis as a late sequela of cancer treatment, Clin Gastroenterol Hepatol, 12, 1046, 10.1016/j.cgh.2013.11.040 Zheng, 2021, Comprehensive assessment of diet quality and risk of precursors of early-onset colorectal cancer, J Natl Cancer Inst, 113, 543, 10.1093/jnci/djaa164 Feldman, 2022, Clinical features and long-term outcomes of patients with colonic oligopolyposis of unknown etiology, World J Gastroenterol, 28, 6950, 10.3748/wjg.v28.i48.6950 Jelsig, 2021, Danish guidelines for management of non-APC-associated hereditary polyposis syndromes, Hered Cancer Clin Pract, 19, 41, 10.1186/s13053-021-00197-8 Latchford, 2022, Gastrointestinal aspects of Peutz-Jeghers syndrome, Best Pract Res Clin Gastroenterol, 58-59, 10.1016/j.bpg.2022.101789 Utsunomiya, 1975, Peutz-Jeghers syndrome: its natural course and management, Johns Hopkins Med J, 136, 71 Giardiello, 2006, Peutz-Jeghers syndrome and management recommendations, Clin Gastroenterol Hepatol, 4, 408, 10.1016/j.cgh.2005.11.005 Boland, 2022, Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the US multi-society task force on colorectal cancer, Gastroenterology, 162, 2063, 10.1053/j.gastro.2022.02.021 Giardiello, 2000, Very high risk of cancer in familial Peutz-Jeghers syndrome, Gastroenterology, 119, 1447, 10.1053/gast.2000.20228 Sandru, 2021, Peutz-Jeghers syndrome: skin manifestations and endocrine anomalies (Review), Exp Ther Med, 22, 1387, 10.3892/etm.2021.10823 Jenne, 1998, Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase, Nat Genet, 18, 38, 10.1038/ng0198-38 Latchford, 2011, Peutz-Jeghers syndrome: intriguing suggestion of gastrointestinal cancer prevention from surveillance, Dis Colon Rectum, 54, 1547, 10.1097/DCR.0b013e318233a11f Wei, 2009, Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model, Cancer Lett, 277, 149, 10.1016/j.canlet.2008.11.036 Kuwada, 2011, A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome, Fam Cancer, 10, 469, 10.1007/s10689-011-9471-9 de Brabander, 2018, Chemoprevention in patients with peutz-jeghers syndrome: lessons learned, Oncol, 23, 399-e33, 10.1634/theoncologist.2017-0682 Udd, 2004, Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2, Gastroenterology, 127, 1030, 10.1053/j.gastro.2004.07.059 Latchford, 2012, Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome, Dis Colon Rectum, 55, 1038, 10.1097/DCR.0b013e31826278b3 Ma, 2018, Pathology and genetics of hereditary colorectal cancer, Pathology, 50, 49, 10.1016/j.pathol.2017.09.004 Zbuk, 2007, Hamartomatous polyposis syndromes, Nat Clin Pract Gastroenterol Hepatol, 4, 492, 10.1038/ncpgasthep0902 Dal Buono, 2022, Juvenile polyposis syndrome: an overview, Best Pract Res Clin Gastroenterol, 58-59, 10.1016/j.bpg.2022.101799 MacFarland, 2021, Phenotypic differences in juvenile polyposis syndrome with or without a disease-causing SMAD4/BMPR1A variant, Cancer Prev Res, 14, 215, 10.1158/1940-6207.CAPR-20-0348 Brosens, 2007, Risk of colorectal cancer in juvenile polyposis, Gut, 56, 965, 10.1136/gut.2006.116913 Howe, 1998, The risk of gastrointestinal carcinoma in familial juvenile polyposis, Ann Surg Oncol, 5, 751, 10.1007/BF02303487 Bell, 2022, Polygenic infantile juvenile polyposis syndrome managed with sirolimus and endoscopic polypectomy, Gastroenterol Res, 15, 33, 10.14740/gr1480 Martin-Masot, 2021, Sirolimus for the treatment of juvenile polyposis in childhood, ACG case reports journal, 8, 10.14309/crj.0000000000000646 Busoni, 2019, Successful treatment of juvenile polyposis of infancy with sirolimus, Pediatrics, 144, 10.1542/peds.2018-2922 D'Ermo, 2022, Gastrointestinal manifestations in PTEN hamartoma tumor syndrome, Best Pract Res Clin Gastroenterol, 58-59, 10.1016/j.bpg.2022.101792 Heald, 2010, Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers, Gastroenterology, 139, 1927, 10.1053/j.gastro.2010.06.061 Nieuwenhuis, 2012, Is colorectal surveillance indicated in patients with PTEN mutations?, Colorectal Dis, 14, e562, 10.1111/j.1463-1318.2012.03121.x Riegert-Johnson, 2010, Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients, Hered Cancer Clin Pract, 8, 6, 10.1186/1897-4287-8-6 Tan, 2012, Lifetime cancer risks in individuals with germline PTEN mutations, Clin Cancer Res : Off J Am Assoc Cancer Res, 18, 400, 10.1158/1078-0432.CCR-11-2283 Stanich, 2014, Colonic manifestations of PTEN hamartoma tumor syndrome: case series and systematic review, World J Gastroenterol, 20, 1833, 10.3748/wjg.v20.i7.1833 Khare, 2022, Endoscopic findings in patients with PTEN hamartoma tumor syndrome undergoing surveillance, J Clin Gastroenterol, 56, e183, 10.1097/MCG.0000000000001580 Syngal, 2015, ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes, Am J Gastroenterol, 110, 223, 10.1038/ajg.2014.435 Smerdel, 2020, Revised Danish guidelines for the cancer surveillance of patients with Cowden Syndrome, Eur J Med Genet, 63, 10.1016/j.ejmg.2020.103873 Tischkowitz, 2020, Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome, Eur J Hum Genet, 28, 1387, 10.1038/s41431-020-0651-7 Squarize, 2008, Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin, Cancer Res, 68, 7066, 10.1158/0008-5472.CAN-08-0922 Komiya, 2019, A pilot study of sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN, Oncol, 24, 1510-e265, 10.1634/theoncologist.2019-0514 Song, 2020, Serrated polyposis syndrome: increasing awareness and importance, Cureus, 12 JEG, 2017, Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview, Gut, 66, 1225, 10.1136/gutjnl-2015-310784 Rodriguez-Alcalde, 2019, High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome, Endoscopy, 51, 142, 10.1055/a-0656-5557 Boparai, 2010, Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome, Gut, 59, 1222, 10.1136/gut.2009.200741 Yan, 2017, RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation, Gut, 66, 1645, 10.1136/gutjnl-2016-311849 Buchanan, 2017, Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study, Gut, 66, 1170, 10.1136/gutjnl-2016-312773 Dekker, 2020, Dutch-Spanish-British serrated polyposis syndrome c. Update on the world health organization criteria for diagnosis of serrated polyposis syndrome, Gastroenterology, 158, 1520, 10.1053/j.gastro.2019.11.310 Whitelaw, 1997, Clinical and molecular features of the hereditary mixed polyposis syndrome, Gastroenterology, 112, 327, 10.1053/gast.1997.v112.pm9024286 Jaeger, 2012, Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1, Nat Genet, 44, 699, 10.1038/ng.2263 McKenna, 2019, Identification of a novel GREM1 duplication in a patient with multiple colon polyps, Fam Cancer, 18, 63, 10.1007/s10689-018-0090-6 Lieberman, 2017, Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance, Gastroenterology, 152, 1876, 10.1053/j.gastro.2017.02.014 Lowery, 2016, Understanding the contribution of family history to colorectal cancer risk and its clinical implications: a state-of-the-science review, Cancer, 122, 2633, 10.1002/cncr.30080 Kerber, 2005, Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database, Fam Cancer, 4, 239, 10.1007/s10689-005-0657-x Schoen, 2015, Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer, Gastroenterology, 149, 1438, 10.1053/j.gastro.2015.07.055 Fuchs, 1994, A prospective study of family history and the risk of colorectal cancer, N Engl J Med, 331, 1669, 10.1056/NEJM199412223312501 Song, 2021, Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden, BMJ, 373 Samadder, 2015, Increased risk of colorectal cancer among family members of all ages, regardless of age of index case at diagnosis, Clin Gastroenterol Hepatol, 13, 10.1016/j.cgh.2015.06.040 Johns, 2001, A systematic review and meta-analysis of familial colorectal cancer risk, Am J Gastroenterol, 96, 2992, 10.1111/j.1572-0241.2001.04677.x Shaukat, 2021, ACG clinical guidelines: colorectal cancer screening 2021, Am J Gastroenterol, 116, 458, 10.14309/ajg.0000000000001122 van Leerdam, 2019, Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Endoscopy, 51, 1082, 10.1055/a-1016-4977 Choi, 2019, Risks of colorectal cancer and cancer-related mortality in familial colorectal cancer type X and lynch syndrome families, J Natl Cancer Inst, 111, 675, 10.1093/jnci/djy159 Therkildsen, 2020, Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort, BMC Cancer, 20, 345, 10.1186/s12885-020-06859-5 Bucksch, 2020, Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study, BMC Cancer, 20, 460, 10.1186/s12885-020-06926-x Lindor, 2005, Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X, JAMA, 293, 1979, 10.1001/jama.293.16.1979 Xu, 2020, Comparison between familial colorectal cancer type X and lynch syndrome: molecular, clinical, and pathological characteristics and pedigrees, Front Oncol, 10, 1603, 10.3389/fonc.2020.01603 Garcia, 2022, New insights on familial colorectal cancer type X syndrome, Sci Rep, 12, 2846, 10.1038/s41598-022-06782-8 Zetner, 2017, Familial colorectal cancer type X, Curr Genom, 18, 341, 10.2174/1389202918666170307161643 Wagner, 2021, The management of Peutz–Jeghers syndrome: European hereditary tumour group (EHTG) guideline, J Clin Med, 10, 473, 10.3390/jcm10030473 Giardiello, 2014, Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the us multi-society task force on colorectal cancer, Gastroenterology [Internet], 147, 502, 10.1053/j.gastro.2014.04.001 Herzig, 2017, Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome, Dis Colon Rectum, 60, 137, 10.1097/DCR.0000000000000785 Tomita, 2021, Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer, Int J Clin Oncol, 26, 1353, 10.1007/s10147-021-01881-4